Introduction
============

Acute kidney injury (AKI) is a serious complication of PCI and is associated with an increased risk of myocardial infarction, dialysis and death.^[@b1]--[@b5]^ It is common, with a reported incidence after PCI of between 3% and 19% and can be mitigated by the use of hydration and the avoidance of excess contrast.^[@b6]--[@b9]^ It is also associated with a number of pre‐procedural clinical factors such as pre‐existing chronic kidney disease that make it an ideal target for risk modeling. However, previous models of AKI were developed over 10 years ago, prior to the contemporary use of hydration protocols and low‐osmolar contrast agents, and were not based on the Acute Kidney Injury Network (AKIN) criteria, which has become the contemporary consensus criteria for defining AKI.^[@b2],[@b5],[@b10]^ Moreover, the importance of such a model has expanded in the current era, where there is a growing focus on safety, quality improvement, patient‐centered care, and personalized medicine.^[@b11]--[@b12]^

With respect to quality assessment and improvement, the American College of Cardiology (ACC) sought to provide risk‐adjusted AKI rates to hospitals participating in its National Cardiovascular Data Registry (NCDR) so that comparative benchmarking and quality improvement could occur. Moreover, by prospectively knowing the AKI risk of an individual patient, it would also be possible to tailor treatment (eg, use of hydration protocols, low‐osmolar contrast agents, staging of multi‐vessel PCI procedures for patient safety reasons to minimize acute contrast exposure, etc.) to maximize safety and outcomes. Risk‐adjusted models of other outcomes are increasingly being used to facilitate medical decision making,^[@b13]^ personalize informed consent documents,^[@b14]^ and support quality improvement efforts^[@b15]^ and have been used in to improve patients\' engagement and understanding of the risks and benefits of PCI.^[@b16]--[@b19]^ Accordingly, we used the ACC NCDR to develop and validate a parsimonious risk model for AKI and AKI requiring dialysis (AKI‐D) to support more accurate informed consent, safer care, and quality improvement.

Methods
=======

Study Population
----------------

The NCDR Cath‐PCI registry, co‐sponsored by the ACC and the Society for Cardiovascular Angiography and Interventions, has been previously described.^[@b20]--[@b21]^ The registry catalogs data on patient and hospital characteristics, clinical presentation, treatments, and outcomes associated with PCI from \>1000 sites across the United States. The data are entered into ACC‐certified software at participating institutions. There is a comprehensive data quality program, including both data quality report specifications for data capture and transmission and an auditing program.^[@b22]^ The data collected are exported in a standard format to the ACC Heart House (Washington, DC). Complete definitions of all variables were prospectively defined by an ACC committee and are available at the ACC NCDR web site (<http://www.acc.org/ncdr/cathlab.htm>).

For this study, we identified all patients receiving PCI between June 1, 2009 and June 30, 2011 enrolled in the NCDR CathPCI Registry (N=1 254 089). We excluded patients discharged on the day of their procedure (n=42 029; 3.4%), without a pre‐ and post‐procedure serum creatinine (n=207 789; 16.6%), patients undergoing multiple PCI\'s during a single hospitalization (n=32 999; 2.6%), and patients currently on dialysis at the time of their PCI (n=24 517; 2.0%). The final analytic cohort included 947 012 patients receiving PCI that were randomly divided into a 70% derivation (n=662 504) and 30% validation cohort (n=284 508; [Figure 1](#fig01){ref-type="fig"}). A comparison of those with and without creatinine levels before or after their procedure with those included in the cohort revealed minimal differences (results available from authors upon request).
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Study Outcomes and Variables
----------------------------

The primary outcome was AKI, using the change from pre‐procedure to peak serum creatinine after the procedure. We used the contemporary standardized definition for AKI as described by the Acute Kidney Injury Network for Stage 1 or greater injury, which is defined as a ≥0.3 mg/dL absolute or ≥1.5‐fold relative increase in post‐PCI creatinine or new initiation of dialysis.^[@b23]^ As urine output is not collected within the NCDR registry, this facet of the definition was omitted, which may have led to some patients developing a reduction in urine output without a rise in their creatinine being misclassified as not having AKI. AKI requiring dialysis (AKI‐D) was identified using a pre‐defined NCDR data element for acute or worsening renal failure necessitating new renal dialysis by the participating centers. Patients with AKI‐D were included in the AKI group but were also examined separately, given its clinical importance, to identify independent predictors for requiring dialysis after PCI.

Framing of the Analysis
-----------------------

The purpose of risk‐adjustment to support quality assessment/improvement or tailored approaches to treatment is to account for patient characteristics prior to the initiation of treatment.^[@b24]^ We therefore considered potential predictor variables to be those that existed prior to the initiation of PCI. Although contrast is clearly known to be associated with the development of AKI and AKI‐D, it was not considered as a potential predictor as the amount of contrast needed is not known at the start of PCI, varies substantially by operator and hospital, and may mask differences in the safety of PCI across centers if it were accounted for in the risk model.

Data Analysis
-------------

Data are described as proportions or mean±SD. Baseline patient characteristics and variables with clinical or statistically significant associations with both AKI and AKI‐D were included in separate multivariable logistic regression models. In the derivation cohort, iterative model construction was used to identify significant bivariate associations of clinically relevant variables with AKI and dialysis. The full list of candidate variables included: Age, Gender, BMI, IABP Before Procedure, baseline CKD status (mild=eGFR 45 to 60, moderate=30 to 45, severe \<30 mL/min), HF within the prior 2 weeks, Diabetes, Hypertension, Prior MI, Prior HF, Prior PCI, Prior CABG, Prior CVD, Prior PAD, CLD, NSTEMI/Unstable Angina, STEMI, Prior Shock, Prior Cardiac Arrest, Anemia (Hgb\<10), and Transfer‐in Status. Missing categorical variables (\<1%) were imputed to the most common value, and missing continuous variables were imputed to relevant group‐specific medians.

To create a more parsimonious, practical model for clinical use, variables were ranked by the strength of their association with AKI and sequentially removed until the adjusted *R*^2^ of the logistic regression model reached 95% of the full model.^[@b25]^ The loss of discriminatory power with the reduced model was compared with the full model using the computed integrated discrimination improvement (IDI)^[@b26]^ and the difference in c‐statistics. To further support prospective clinical use of the model, we created a simple integer‐scoring model by assigning a weighted integer coefficient value corresponding to each variable\'s β‐weight for the prediction of both AKI and AKI‐D.^[@b27]^

Finally, model calibration and discrimination for both the full and integer models of AKI and AKI‐D were evaluated in the 30% validation sample using the c‐statistics and the slope of the predicted versus observed rates of AKI/Dialysis within deciles of predicted AKI/Dialysis risk. SAS (version 9.2; SAS Institute, Cary, NC) statistical software was used for all statistical testing.

Sensitivity Analysis
--------------------

To address whether a single model can adequately risk stratify patients with distinctly different clinical settings, we tested a number of interaction terms including, STEMI, NSTEMI, and baseline CKD and a spline term for age. None of the interaction terms were significant suggesting the model performed well in those patient subsets and arguing against separate models. Observed versus expected plots for the clinically important subsets of patients with severe CKD, STEMI, NSTEMI, and Non‐ACS were also examined and the c‐statistics and calibration slope of the model within each subgroup assessed.

Results
=======

Baseline characteristics, in‐hospital treatments, and outcomes of the 662 504 patients used to develop the model (derivation cohort) and 284 508 used to test the model (validation cohort) are shown in [Table 1](#tbl01){ref-type="table"}. There were no statistically or clinically significant differences in baseline demographics, comorbidities, treatment, or outcomes between the derivation and validation cohorts. The mean age was 64.8±12.2 years and 67% were men. More than 80% had a history of hypertension and hyperlipidemia, with 28% either currently smoking or having quit within the past year. Approximately 36% of patients had a history of diabetes and 30% had a history of myocardial infarction. Most patients underwent PCI for an acute coronary syndrome, either high‐risk NSTEMI/unstable angina (55.3%) or immediate PCI for STEMI (15.7%).

###### 

Baseline Characteristics of the Cohorts

                                                        Total (n = 947 012)   Cohort             
  ----------------------------------------------------- --------------------- ------------------ ------------------
  Demographics                                                                                   
  Age, y                                                64.8±12.2             64.8±12.2          64.9±12.2
  Sex                                                                                            
  Male                                                  635 967 (67.2%)       445 016 (67.2%)    190 951 (67.1%)
  Female                                                311 045 (32.8%)       217 488 (32.8%)    93 557 (32.9%)
  Race                                                                                           
  White                                                 838 384 (88.5%)       586 634 (88.5%)    251 750 (88.5%)
  Black or African American                             74 840 (7.9%)         52 341 (7.9%)      22 499 (7.9%)
  Body mass index                                       30.1±11.8             30.1±11.1          30.1±13.2
  Baseline GFR                                                                                   
  Mean GFR                                              72.9±22.6             72.9±22.6          72.9±22.6
  GFR level                                                                                      
  Normal GFR ≥60                                        670 408 (70.8%)       468 966 (70.8%)    201 442 (70.8%)
  Mild GFR 45 to 60                                     161 968 (17.1%)       113 230 (17.1%)    48 738 (17.1%)
  Moderate GFR 30 to 45                                 86 811 (9.2%)         60 875 (9.2%)      25 936 (9.1%)
  Severe GFR \<30                                       27 664 (2.9%)         19 318 (2.9%)      8346 (2.9%)
  History                                                                                        
  Anemia                                                34 994 (3.7%)         24 500 (3.7%)      10 494 (3.7%)
  Current/recent smoker (within 1 year)                 264 100 (27.9%)       184 900 (27.9%)    79 200 (27.9%)
  Hypertension                                          774 402 (81.8%)       541 819 (81.8%)    232 583 (81.7%)
  Dyslipidemia                                          756 834 (80.0%)       529 302 (80.0%)    227 532 (80.1%)
  Family history of premature CAD                       231 480 (24.5%)       162 086 (24.5%)    69 394 (24.4%)
  Prior MI                                              282 294 (29.8%)       197 560 (29.8%)    84 734 (29.8%)
  Prior heart failure                                   109 973 (11.6%)       77 072 (11.6%)     32 901 (11.6%)
  Prior valve surgery/procedure                         13 880 (1.5%)         9582 (1.4%)        4298 (1.5%)
  Prior PCI                                             376 113 (39.7%)       262 832 (39.7%)    113 281 (39.8%)
  Prior CABG                                            176 030 (18.6%)       123 078 (18.6%)    52 952 (18.6%)
  Cerebrovascular disease                               115 909 (12.2%)       81 093 (12.2%)     34 816 (12.2%)
  Peripheral arterial disease                           116 008 (12.2%)       81 280 (12.3%)     34 728 (12.2%)
  Chronic lung disease                                  144 137 (15.2%)       101 031 (15.2%)    43 106 (15.2%)
  Diabetes mellitus                                     339 158 (35.8%)       237 100 (35.8%)    102 058 (35.9%)
  Cath lab presentation                                                                          
  CAD presentation                                                                               
  No symptom, no angina                                 89 318 (9.4%)         62 495 (9.4%)      26 823 (9.4%)
  Symptom unlikely to be ischemic                       27 610 (2.9%)         19 347 (2.9%)      8263 (2.9%)
  Stable angina                                         157 610 (16.6%)       110 524 (16.7%)    47 086 (16.6%)
  Unstable angina                                       344 792 (36.4%)       240 946 (36.4%)    103 846 (36.5%)
  Non‐STEMI                                             178 569 (18.9%)       124 983 (18.9%)    53 586 (18.8%)
  ST‐Elevation MI (STEMI) or equivalent                 148 797 (15.7%)       103 991 (15.7%)    44 806 (15.8%)
  Anginal classification within 2 weeks                                                          
  No symptoms                                           130 327 (13.8%)       91 224 (13.8%)     39 103 (13.8%)
  CCS I                                                 58 543 (6.2%)         40 881 (6.2%)      17 662 (6.2%)
  CCS II                                                189 328 (20.1%)       132 556 (20.1%)    56 772 (20.0%)
  CCS III                                               300 612 (31.9%)       210 536 (31.9%)    90 076 (31.8%)
  CCS IV                                                264 940 (28.1%)       184 999 (28.0%)    79 941 (28.2%)
  IABP before procedure                                 2329 (0.2%)           1651 (0.2%)        678 (0.2%)
  Anti‐anginal medication within 2 weeks                649 300 (68.6%)       454 279 (68.6%)    195 021 (68.6%)
  Heart failure within 2 weeks                          95 633 (10.1%)        67 262 (10.2%)     28 371 (10.0%)
  Left ventricular systolic dysfunction                 94 346 (10.0%)        66 321 (10.0%)     28 025 (9.9%)
  Pre‐operative evaluation before non‐cardiac surgery   17 035 (1.8%)         11 901 (1.8%)      5134 (1.8%)
  Cardiogenic shock within 24 hours                     17 125 (1.8%)         12 002 (1.8%)      5123 (1.8%)
  Cardiac arrest within 24 hours                        16 983 (1.8%)         11 813 (1.8%)      5170 (1.8%)
  Multiple procedures                                   62 299 (6.6%)         43 645 (6.6%)      18 654 (6.6%)
  Pre‐PCI left ventricular ejection fraction            52.3±12.5             52.3±12.5          52.3±12.5
  Contrast use and IABP during procedure                                                         
  Average contrast volume                               198.9±91.2            198.9±91.2         198.9±91.0
  Average contrast/GFR ratio                            3.1±2.5               3.1±2.5            3.1±2.5
  Level of contrast/GFR ratio                                                                    
  Contrast/GFR \<2×                                     287 084 (30.4%)       201 001 (30.4%)    86 083 (30.4%)
  Contrast/GFR 2× to 3×                                 284 245 (30.1%)       198 900 (30.1%)    85 345 (30.1%)
  Contrast/GFR \>3×                                     372 453 (39.5%)       260 353 (39.4%)    112 100 (39.5%)
  Contrast volumes                                                                               
  Contrast volume 0 to 50 mL                            16 307 (1.7%)         11 504 (1.7%)      4803 (1.7%)
  Contrast volume 51 to 100                             96 475 (10.2%)        67 494 (10.2%)     28 981 (10.2%)
  Contrast volume 101 to 150                            212 242 (22.5%)       148 464 (22.5%)    63 778 (22.5%)
  Contrast volume 151 to 200                            244 911 (25.9%)       171 311 (25.9%)    73 600 (26.0%)
  Contrast volume 201 to 250                            170 088 (18.0%)       118 954 (18.0%)    51 134 (18.0%)
  Contrast volume 251 to 300                            100 654 (10.7%)       70 397 (10.7%)     30 257 (10.7%)
  Contrast volume 301 to 350                            49 377 (5.2%)         34 520 (5.2%)      14 857 (5.2%)
  Contrast volume 351 to 400                            27 028 (2.9%)         18 891 (2.9%)      8137 (2.9%)
  Contrast volume \>400                                 26 859 (2.8%)         18 832 (2.9%)      8027 (2.8%)
  Fluoroscopy time                                      14.7±11.6             14.7±11.7          14.6±11.6
  IABP                                                  23 718 (2.5%)         16 508 (2.5%)      7210 (2.5%)
  In‐ hospital outcomes                                                                          
  Discharge status                                                                               
  Alive                                                 936 750 (98.9%)       655 352 (98.9%)    281 398 (98.9%)
  Deceased                                              10 258 (1.1%)         7149 (1.1%)        3109 (1.1%)
  CVA/stroke                                            2325 (0.2%)           1639 (0.2%)        686 (0.2%)
  Other vascular complications requiring treatment      4535 (0.5%)           3182 (0.5%)        1353 (0.5%)
  Length of stay                                        2.3±4.4               2.3±4.5            2.3±4.4
  RBC/whole blood transfusion                           27 788 (2.9%)         19 482 (2.9%)      8306 (2.9%)
  AKI rates                                                                                      
  Pre‐procedure creatinine                              1.1±0.5               1.1±0.5            1.1±0.5
  Post‐procedure creatinine                             1.1±0.6               1.1±0.6            1.1±0.6
  AKI stage                                                                                      
  No AKI                                                877 559 (92.67%)      613 911 (92.67%)   263 648 (92.67%)
  Stage I                                               59 659 (6.3%)         41 768 (6.3%)      17 891 (6.3%)
  Stage II                                              4507 (0.5%)           3143 (0.5%)        1364 (0.5%)
  Stage III                                             2412 (0.3%)           1703 (0.3%)        709 (0.2%)
  New dialysis                                          2875 (0.3%)           1979 (0.3%)        896 (0.3%)

AKI indicates acute kidney injury; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society classification; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.

Overall, 1.1% of patients died in the hospital with 7.1% developing AKI and 0.3% developing AKI‐D. In‐hospital AKI was similar in the development (7.3%, n=48 818) and validation cohorts (7.3%, n=20 849). The baseline characteristics of those who did and did not develop AKI are shown in [Table 2](#tbl02){ref-type="table"}.

###### 

Characteristics of Those With and Without AKI in the Derivation Cohort

                                                        Total (n=662 504)   AKI Category     *P* Value          
  ----------------------------------------------------- ------------------- ---------------- ------------------ ---------
  Demographics                                                                                                  
  Age, y                                                64.8±12.2           68.2±12.4        64.6±12.1          \<0.001
  Sex                                                                                                           
  Male                                                  445 016 (67.2%)     29 724 (61.2%)   415 292 (67.6%)    \<0.001
  Female                                                217 488 (32.8%)     18 869 (38.8%)   198 619 (32.4%)    
  Race                                                                                                          
  White                                                 586 634 (88.5%)     41 574 (85.6%)   545 060 (88.8%)    \<0.001
  Black or African American                             52 341 (7.9%)       5212 (10.7%)     47 129 (7.7%)      \<0.001
  Body mass index                                       30.1±11.1           30.5±16.9        30.0±10.6          \<0.001
  Baseline GFR                                                                                                  
  Mean GFR                                              72.9±22.6           64.2±28.3        73.6±21.9          \<0.001
  GFR level                                                                                                     
  Normal GFR ≥60                                        468 966 (70.8%)     25 439 (52.5%)   443 527 (72.2%)    \<0.001
  Mild GFR 45 to 60                                     113 230 (17.1%)     9669 (19.9%)     103 561 (16.9%)    
  Moderate GFR 30 to 45                                 60 875 (9.2%)       8222 (17.0%)     52 653 (8.6%)      
  Severe GFR \<30                                       19 318 (2.9%)       5148 (10.6%)     14170 (2.3%)       
  History                                                                                                       
  Anemia                                                24 500 (3.7%)       5123 (10.5%)     19 377 (3.2%)      \<0.001
  Current/recent smoker (within 1 year)                 184 900 (27.9%)     11 396 (23.5%)   173 504 (28.3%)    \<0.001
  Hypertension                                          541 819 (81.8%)     42 130 (86.7%)   499 689 (81.4%)    \<0.001
  Dyslipidemia                                          529 302 (80.0%)     37 815 (77.9%)   491 487 (80.1%)    \<0.001
  Family history of premature CAD                       162 086 (24.5%)     9743 (20.1%)     152 343 (24.8%)    \<0.001
  Prior MI                                              197 560 (29.8%)     15 799 (32.5%)   181 761 (29.6%)    \<0.001
  Prior heart failure                                   77 072 (11.6%)      11 056 (22.8%)   66 016 (10.8%)     \<0.001
  Prior valve surgery/procedure                         9582 (1.4%)         979 (2.0%)       8603 (1.4%)        \<0.001
  Prior PCI                                             262 832 (39.7%)     17 738 (36.5%)   245 094 (39.9%)    \<0.001
  Prior CABG                                            123 078 (18.6%)     10 356 (21.3%)   112 722 (18.4%)    \<0.001
  Cerebrovascular disease                               81 093 (12.2%)      8984 (18.5%)     72 109 (11.7%)     \<0.001
  Peripheral arterial disease                           81 280 (12.3%)      8906 (18.3%)     72 374 (11.8%)     \<0.001
  Chronic lung disease                                  101 031 (15.2%)     9902 (20.4%)     91 129 (14.8%)     \<0.001
  Diabetes mellitus                                     237 100 (35.8%)     23 875 (49.1%)   213 225 (34.7%)    \<0.001
  Cath lab presentation                                                                                         
  CAD presentation                                                                                              
  No symptom, no angina                                 62 495 (9.4%)       3700 (7.6%)      58 795 (9.6%)      \<0.001
  Symptom unlikely to be ischemic                       19 347 (2.9%)       1283 (2.6%)      18 064 (2.9%)      
  Stable angina                                         110 524 (16.7%)     4563 (9.4%)      105 961 (17.3%)    
  Unstable angina                                       240 946 (36.4%)     14 156 (29.1%)   226 790 (37.0%)    
  Non‐STEMI                                             124 983 (18.9%)     13 162 (27.1%)   111 821 (18.2%)    
  ST‐Elevation MI (STEMI) or equivalent                 103 991 (15.7%)     11 718 (24.1%)   92 273 (15.0%)     
  Anginal classification within 2 weeks                                                                         
  No symptoms                                           91 224 (13.8%)      6791 (14.0%)     84 433 (13.8%)     \<0.001
  CCS I                                                 40 881 (6.2%)       2098 (4.3%)      38 783 (6.3%)      
  CCS II                                                132 556 (20.1%)     6770 (14.0%)     125 786 (20.6%)    
  CCS III                                               210 536 (31.9%)     14 280 (29.5%)   196 256 (32.1%)    
  CCS IV                                                184 999 (28.0%)     18 478 (38.2%)   166 521 (27.2%)    
  IABP before procedure                                 1651 (0.2%)         560 (1.2%)       1091 (0.2%)        \<0.001
  Anti‐anginal medication within 2 weeks                454 279 (68.6%)     34 448 (70.9%)   419 831 (68.4%)    \<0.001
  Heart failure within 2 weeks                          67 262 (10.2%)      12 157 (25.0%)   55 105 (9.0%)      \<0.001
  Left ventricular systolic dysfunction                 66 321 (10.0%)      8680 (17.9%)     57 641 (9.4%)      \<0.001
  Pre‐operative evaluation before non‐cardiac surgery   11 901 (1.8%)       806 (1.7%)       11 095 (1.8%)      0.018
  Cardiogenic shock within 24 hours                     12 002 (1.8%)       4028 (8.3%)      7974 (1.3%)        \<0.001
  Cardiac arrest within 24 hours                        11 813 (1.8%)       2766 (5.7%)      9047 (1.5%)        \<0.001
  Multiple procedures in hospital                       43 645 (6.6%)       4529 (9.3%)      39 116 (6.4%)      \<0.001
  Pre‐PCI left ventricular ejection fraction            52.3±12.5           46.8±15.0        52.7±12.3          \<0.001
  Contrast use and IABP during procedure                                                                        
  Contrast volume                                       198.9±91.2          206.9±101.2      198.3±90.4         \<0.001
  Average contrast/GFR ratio                            3.1±2.5             4.1±3.9          3.0±2.3            \<0.001
  Ratio level                                                                                                   
  Contrast/GFR \<2×                                     201 001 (30.4%)     11 119 (23.0%)   189 882 (31.0%)    \<0.001
  Contrast/GFR 2× to 3×                                 198 900 (30.1%)     11 407 (23.6%)   187 493 (30.6%)    
  Contrast/GFR \>3×                                     260 353 (39.4%)     25 778 (53.4%)   234 575 (38.3%)    
  Contrast level                                                                                                
  Contrast volume 0 to 50                               11 504 (1.7%)       945 (2.0%)       10 559 (1.7%)      \<0.001
  Contrast volume 51 to 100                             67 494 (10.2%)      5002 (10.3%)     62 492 (10.2%)     
  Contrast volume 101 to 150                            148 464 (22.5%)     10 171 (21.0%)   138 293 (22.6%)    
  Contrast volume 151 to 200                            171 311 (25.9%)     11 724 (24.2%)   159 587 (26.1%)    
  Contrast volume 201 to 250                            118 954 (18.0%)     8530 (17.6%)     110 424 (18.0%)    
  Contrast volume 251 to 300                            70 397 (10.7%)      5450 (11.3%)     64 947 (10.6%)     
  Contrast volume 301 to 350                            34 520 (5.2%)       2832 (5.8%)      31 688 (5.2%)      
  Contrast volume 351 to 400                            18 891 (2.9%)       1709 (3.5%)      17 182 (2.8%)      
  Contrast volume \>400                                 18 832 (2.9%)       2054 (4.2%)      16 778 (2.7%)      
  Fluoroscopy time                                      14.7±11.7           17.0±13.6        14.5±11.5          \<0.001
  IABP                                                  16 508 (2.5%)       5338 (11.0%)     11 170 (1.8%)      \<0.001
  In‐hospital outcomes                                                                                          
  Discharge status                                                                                              
  Alive                                                 655 352 (98.9%)     44 245 (91.1%)   611 107 (99.5%)    \<0.001
  Deceased                                              7149 (1.1%)         4348 (8.9%)      2801 (0.5%)        
  CVA/stroke                                            1639 (0.2%)         524 (1.1%)       1115 (0.2%)        \<0.001
  Other vascular complications requiring treatment      3182 (0.5%)         738 (1.5%)       2444 (0.4%)        \<0.001
  LOS                                                   2.3±4.5             5.6±7.8          2.0±4.0            \<0.001
  RBC/whole blood transfusion                           19482 (2.9%)        7384 (15.2%)     12 098 (2.0%)      \<0.001
  AKI                                                                                                           
  Pre‐procedure creatinine                              1.1±0.5             1.3±0.8          1.1±0.5            \<0.001
  Post‐procedure creatinine                             1.1±0.6             2.1±1.4          1.0±0.4            \<0.001
  New requirement for dialysis                          1979 (0.3%)         1979 (4.1%)      0 (0.0%)           \<0.001
  Akistage                                                                                                      
  No AKI                                                613 911 (92.7%)     0 (0.0%)         613 911 (100.0%)   \<0.001
  Stage I                                               41 768 (6.3%)       41 768 (86.0%)   0 (0.0%)           
  Stage II                                              3143 (0.5%)         3143 (6.5%)      0 (0.0%)           
  Stage III                                             1703 (0.3%)         1703 (3.5%)      0 (0.0%)           
  New dialysis                                          1979 (0.3%)         1979 (4.1%)      0 (0.0%)           

Continuous variables compared using Student *t* test. Categorical variables compared using chi‐square or Fisher\'s exact test. AKI indicates acute kidney injury; CAD, coronary artery disease; CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society Classification; LOS, length of stay; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.

Initially, 24 independent predictors for AKI and AKI‐D were identified the multivariable modeling in the derivation cohort, resulting in a model c‐statistics of 0.72 and 0.89, respectively. After removing 10 and 16 variables from the models, the final models included 11 multivariate predictors for AKI (c‐stat 0.71; [Figure 2](#fig02){ref-type="fig"}) and 6 for AKI‐D (c‐stat 0.88; [Figure 3](#fig03){ref-type="fig"}). The IDI comparing the full to reduced AKI model was 0.0024 (95% CI=0.0022, 0.0028), and for dialysis it was 0.0039 (95% CI=0.0023, 0.0052), indicating little impact on using the reduced model. The 3 variables with the largest predictive ability (defined by total t‐statistic) were STEMI presentation, cardiogenic shock, and baseline CKD. Calibration was confirmed with observed versus predicted plots ([Figure 4](#fig04){ref-type="fig"}) and the slopes for the AKI and AKI‐D predicted versus observed outcomes were 1.001 and 0.99, respectively. The discrimination and calibration in different clinical subsets is shown in [Table 3](#tbl03){ref-type="table"}.

![Predictors of acute kidney injury and their associated odds ratios and 95% confidence intervals. ACS indicates acute coronary syndrome; AKI, acute kidney injury; CKD, chronic kidney disease; CVD, cerebrovascular disease; NSTEMI, non‐ST elevation myocardial infarction.](jah3-3-e001380-g2){#fig02}

![Predictors of acute kidney injury requiring dialysis and their associated odds ratios and 95% confidence intervals. ACS indicates acute coronary syndrome; CKD, chronic kidney disease; STEMI, ST elevation myocardial infarction.](jah3-3-e001380-g3){#fig03}

![Comparison of predicted vs observed outcome rate for the validation cohort (A)AKI; (B)AKI+dialysis. AKI indicates acute kidney injury.](jah3-3-e001380-g4){#fig04}

###### 

Discrimination and Calibration of the AKI Risk Model Across Different Clinical Populations

  Clinical Subgroup                                         Number of Patients in Validation Set   Number of Patients in Derivation Set   c‐Statistic in Validation Cohort   c‐Statistic in Derivation Cohort   Calibration Slope
  --------------------------------------------------------- -------------------------------------- -------------------------------------- ---------------------------------- ---------------------------------- -------------------
  All patients                                              284 508                                662 504                                0.713 (0.709, 0.717)               0.714 (0.711, 0.717)               1.001
  STEMI                                                     44 806                                 103 991                                0.740 (0.732, 0.748)               0.740 (0.735, 0.745)               1.069
  NSTEMI/unstable angina                                    157 432                                365 929                                0.700 (0.694, 0.705)               0.699 (0.695, 0.702)               0.991
  Non‐acute coronary syndrome                               82 270                                 192 584                                0.665 (0.656, 0.674)               0.668 (0.662, 0.674)               0.992
  Severe/moderate reduction in glomerular filtration rate   34 282                                 80 193                                 0.708 (0.701, 0.716)               0.716 (0.711, 0.720)               0.908

AKI indicates acute kidney injury; NSTEMI, non‐ST elevation myocardial infarction.

To create simplified scores for bedside calculation, each variable in each reduced model was then assigned a weighted‐integer coefficient value. The scoring system for AKI and AKI‐D is provided in [Table 4](#tbl04){ref-type="table"}. The IDI for comparing the integer and the full AKI risk model was 0.0067 (95% CI=0.006, 0.007), suggesting a small loss in predictive accuracy. The IDI for the integer model AKI‐D, as compared with the full model predicting AKI‐D, was 0.005 (95% CI=0.001, 0.01). Figures [5](#fig05){ref-type="fig"} and [6](#fig06){ref-type="fig"} illustrate the application of the integer risk score to estimate a prototypical patient\'s risk of AKI and AKI‐D.

###### 

A Simplified Integer Risk Score for Calculating the Risk of AKI and AKI‐D

                      Points   Converting Points to Risk                      
  ------------------- -------- --------------------------- ------ ------ ---- ------
  Age, y                                                                      
  \<50                0                                    0      1.9    0    0.03
  50 to 59            2                                    5      2.6    1    0.05
  60 to 69            4                                    10     3.6    2    0.09
  70 to 79            6                                    15     4.9    3    0.15
  80 to 89            8                                    20     6.7    4    0.27
  \>90                10                                   25     9.2    5    0.48
                                                           30     12.4   6    0.84
  Prior 2 weeks HF    11       2                           35     16.5   7    1.5
  Severe GFR          18       5                           40     217    8    2.6
  Moderate GFR        8        3                           45     27.9   9    4.4
  Mild GFR            3        1                           50     35.1   10   7.6
  Diabetes            7        1                           55     43.0   11   12.6
  Prior HF            4                                    \>60   51.4   12   20.3
  Prior CVD           4                                                  13   31.0
  NSTEMI/UA           6        1                                              
  STEMI               15       2                                              
  Prior card shock    16                                                      
  Prior card arrest   8        3                                              
  Anemia              10                                                      
  IABP                11                                                      

AKI indicates acute kidney injury; HF, heart failure; NSTEMI, non‐ST elevation myocardial infarction.

![NCDR Prediction score card for acute kidney injury following PCI in a sample patient. AKI indicates acute kidney injury; CEA, carotid endarterectomy; CHF, chronic heart failure; eGFR, estimated glomerular filtration rate; HF, heart failure; IABP, intra‐aortic balloon pump; NCDR, National Cardiovascular Data Registry; NSTEMI, non‐ST elevation myocardial infarction; PCI, percutaneous coronary intervention.](jah3-3-e001380-g5){#fig05}

![NCDR prediction score for acute kidney injury requiring dialysis following PCI. HF indicates heart failure; NCDR, National Cardiovascular Data Registry; NSTEMI, non‐ST elevation myocardial infarction.](jah3-3-e001380-g6){#fig06}

Comment
-------

AKI is the most common non‐cardiac complication of PCI, occurring in 1 of every 13 to 14 patients treated. By using the largest available registry of PCI patients, we developed and validated a suite of risk models to predict AKI and AKI‐D in patients undergoing PCI. While the full model is most accurate and appropriate for benchmarking across hospitals, the reduced AKI model included only 11 pre‐procedural variables and the AKI‐D model only 6, rendering them feasible for prospective risk estimation in routine clinical care. We also created a simple integer scoring system for both models to further simplify bedside application, although there was a modest loss in discrimination. These models have the opportunity to both support quality assessment by fairly comparing the AKI rates of hospitals after adjusting for the characteristics of the patients that they treat, but also for supporting personalized medicine and quality improvement by using patient‐level risk prediction to guide PCI treatment strategies, such as limiting contrast exposure, more aggressive hydration protocols, avoiding multivessel PCI in a single setting, or avoiding left ventriculograms in high‐risk patients.

AKI is a serious complication of PCI and is associated with an increased risk of myocardial infarction, dialysis, length of stay,^[@b28]--[@b29]^ healthcare costs, and death.^[@b28],[@b30]--[@b33]^ Previous risk models of AKI post‐PCI, while important contributions at the time, have had limited use in clinical practice. Much of the work was based upon multiple and competing clinical definitions of AKI that varied from an increase in creatinine of 25% to 2 mg/dL, which have led to wide variations in reported AKI rates from 0.7% to 19%.^[@b2],[@b32],[@b34]^ Also, these studies predated the contemporary use of hydration protocols and iso‐osmolar contrast agents, as recommended by societal guidelines and may not reflect contemporary rates of AKI.^[@b35]^ Therefore, our risk model from over 1000 hospitals and nearly 1 million patients uses the recently endorsed definition of AKI from the Acute Kidney Injury Network (AKIN), which has been embraced by the broader medical community as a standard definition.^[@b23],[@b36]^ For example, the Valve Academic Research Consortium (VARC), charged with proposing standardized consensus definitions for important clinical endpoints in future trials and registries of transcatheter aortic valve implantation (TAVI), also chose the AKIN criteria to define AKI. Using the same definition of AKI as chosen for TAVI will allow comparison of AKI rates across different percutaneous procedures.^[@b32]^ Moreover, we have already demonstrated that even Stage 1 AKI, as defined by the AKIN criteria, is associated with increased mortality and bleeding, underscoring the value and importance of using the AKIN criteria.^[@b37]^

Other AKI prediction models have also suffered by the inclusion of intra‐procedural variables, such as contrast dose, which relate more to the skill and quality of decision making by the physician, rather than the inherent risk of the patient.^[@b1],[@b10]^ These models predict patient risk following the procedure and cannot be used for tailoring preventative protocols to patients as a function of their risk, nor can they be used to provide patient‐specific estimates of risk for AKI or dialysis during the informed consent process. Also, few models incorporate the entire spectrum of patients undergoing PCI. Physicians wishing to apply these historical models in routine practice need to be aware that there may be different risk scores for different types of patient undergoing PCI. In the NCDR CathPCI model, we were able to demonstrate that diagnostic prediction for in‐hospital AKI or AKI‐D, regardless of whether the patient presents with STEMI, NSTEMI, or UA, enabling simpler implementation of a single model to accurately, prospectively estimate the risk of AKI for all patients presenting to the cardiac catheterization laboratory. The prospective use of other peri‐procedural risk models, such as the NCDR bleeding model, have been associated with improved safety and outcomes.^[@b19]^ Whether the use of the current model can improve AKI rates needs to be prospectively tested.

Given the challenge by the Institute of Medicine to provide safer, more patient‐centered care, informing patients and clinicians of patients\' personalized risks for PCI is an important step to achieving better healthcare.^[@b11]^ Most recently, NCDR models to predict the patient\'s risk of mortality, bleeding, and target vessel revascularization were used to produce a customized informed‐consent form to better inform patients of treatment options and risks.^[@b14]^ This was compared with usual care and recently assessed in a 9‐center survey of patient experiences. Patients who received the personalized informed consent, based on their own unique pre‐procedural characteristics, showed a significantly greater level of "knowledge transfer" and better understanding of procedural risks. Given that kidney injury and dialysis are common complications of PCI and the variability of risk from patient to patient, vague estimations of risk based on population‐wide data or experience or intuition can be a disservice. Adding patient‐specific estimates of AKI and dialysis risk, derived from the validated preprocedural multivariable models into individualized PCI consent documents can be a significant advance in the consent process for those who are about to undergo PCI.

Certain potential limitations should be considered when interpreting the findings of this study. First, patients and hospitals participating in NCDR may not be representative of all US practices. However, the CathPCI registry represents \>1000 hospitals across the United States and captures the majority of PCIs nationally. Second, we used the in‐hospital pre‐procedure creatinine as the baseline value, which may not have represented the patient\'s true baseline serum creatinine, and did not have access to urine output, which is also a component of the AKIN definitions of AKI. This latter omission may have failed to recognize AKI in those with reduced urine output but no increase in creatinine. Such a bias may also have been introduced in patients whose creatinine rose after discharge but was not increased by \>0.3 mg/dL prior to discharge. Nevertheless, the pre‐procedural and post‐discharge creatinines are what is most commonly available in clinical care and markedly improve feasibility of this model in routine quality assessment. Third, we did not have data on intravenous administration of fluid, concomitant use of renal toxic medications or potentially renal protective medications, all of which may have improved model performance. Importantly, we did not include procedural characteristics, such as the use of left ventriculograms or contrast volume to predict AKI outcomes. While these would have certainly improved the c‐statistics of the models, they are under the locus of control of the physician and are actionable opportunities to improve care.

Conclusions
===========

We developed a valid and robust tool for predicting AKI and AKI‐D in patients undergoing PCI. Use of these models for national quality improvement efforts, personalizing the education of patients about the risks of treatment and to adjust the technical approach to PCI may all lead to safer, higher‐quality care and should be tested in prospective studies.
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